Prevalence of Conjunctivitis and Indentification of Risk Factors With and Without Prophylactic Antibiotic Treatment in Neonates — CRY-NOT  

Ophthalmia Neonatorum Clinical Trial

Official title: Conjunctivitis Incidence in the Newborn Within the First Week of Life: Impact of the Prophylactic Use of Rifamycine(CRY NOT).

Status Completed

Clinical Trial Summary

The French guidelines for the use of Rifamycine eye drops in delivery room to prevent neonatal conjunctivitis have been actualized. Only newborns exposed to risk factors of conjunctivitis should be treated, compared to previous guidelines, treating all newborns. currently, there are no data describing risk factors for neonatal conjunctivitis. This study evaluated the incidence of conjunctivitis with or without Rifamycine eye drops treatment in the delivery room. Then risk factors for neonatal conjunctivitis where analyzed.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Conjunctivitis
• Ophthalmia Neonatorum

• NCT number: NCT03528915
• Study type: Observational
• Source: Centre Hospitalier Universitaire, Amiens
• Status: Completed
• Start date: September 9, 2015
• Completion date: July 24, 2016